The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Around 9,000 people are diagnosed with this kind of cancer every year in the UK, so Brits are being urged to look out for the ...

The HealthWell Foundation®, an independent non-profit charitable organization that provides financial assistance for ...

A father of four who sadly passed away from a rare form of cancer inspired a foundation that hopes to give back.

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

After last week’s essay about this disease condition, it has become necessary to help readers understand the peculiar nature of the organ.